End-to-End Case Processing: From Intake to Regulatory Submission End-to-End Case Processing: From Intake to Regulatory Submission In the realm of pharmacovigilance, the integrity of case processing is paramount for ensuring patient safety and compliance with global regulations. This article serves as a comprehensive guide through the intricacies of case processing, from the initial intake of adverse events to the final regulatory submission. We examine the relevant regulations, guidelines, and agency expectations including those set forth by FDA, EMA, and MHRA. Regulatory Context Pharmacovigilance (PV) is a critical component of drug safety and risk management, ensuring that the benefits of a…

Designing Robust Workflows for ICSR Handling in Global PV Systems Designing Robust Workflows for ICSR Handling in Global PV Systems Pharmacovigilance (PV) plays a critical role in ensuring drug safety and risk management across the globe. The effectiveness of PV systems hinges on the timely and accurate processing of Individual Case Safety Reports (ICSRs). This article elucidates the regulatory framework, guiding principles, and best practices necessary for establishing effective workflows for ICSR handling. The target audience includes professionals in Regulatory Affairs, CMC, and Labelling teams operating within the US, UK, and EU sectors of the pharmaceutical industry. Context: The Importance…

MedDRA Coding, Narrative Quality and Medical Review: What Good Looks Like MedDRA Coding, Narrative Quality and Medical Review: What Good Looks Like Introduction to Regulatory Affairs in Pharmacovigilance Regulatory Affairs (RA) professionals play a critical role in ensuring that pharmaceuticals and biologics meet the legal requirements for safety, efficacy, and quality before they reach the market. In the realm of pharmacovigilance, this entails rigorous oversight of the collection, monitoring, and assessment of adverse drug reactions (ADRs). A key component of this process is the accurate coding and quality of case narratives, which are essential for compliance with Good Vigilance Practice…

EudraVigilance Submissions: Technical, Regulatory and Quality Essentials EudraVigilance Submissions: Technical, Regulatory and Quality Essentials EudraVigilance is the European database that supports the monitoring of safety and efficacy of medicinal products authorized in the European Economic Area (EEA). It plays a critical role in pharmacovigilance by facilitating the collection, management, and analysis of Individual Case Safety Reports (ICSRs) related to adverse drug reactions (ADRs). This article serves as an in-depth regulatory explainer manual outlining the essential elements of EudraVigilance submissions, emphasizing the regulatory requirements, best practices for compliance, and common challenges faced by regulatory affairs professionals. Context The implementation of EudraVigilance…

FAERS Reporting: US-Specific Nuances PV Teams Must Respect FAERS Reporting: US-Specific Nuances PV Teams Must Respect Context Pharmacovigilance (PV) is critical in ensuring drug safety and comprises a series of processes aimed at monitoring, assessing, and mitigating risks associated with pharmaceuticals after they have been authorized for use. In the United States, the Food and Drug Administration (FDA) regulates pharmacovigilance through the Adverse Event Reporting System (FAERS). These regulations are centered on the collection, analysis, and reporting of adverse events, focusing on maintaining drug safety standards and protecting public health. Legal/Regulatory Basis The reporting requirements for adverse events in the…

Balancing Speed and Quality in High-Volume Case Processing Operations Balancing Speed and Quality in High-Volume Case Processing Operations In the evolving landscape of pharmacovigilance (PV), the challenge of balancing speed and quality in high-volume case processing operations is paramount. This article serves as a comprehensive regulatory explainer manual, detailing the relevant guidelines, regulations, and expectations surrounding pharmacovigilance compliance. Our focus will primarily be on the regulatory expectations from agencies such as the FDA, EMA, and MHRA, particularly in areas like case processing, individual case safety report (ICSR) submission, and the integrity of EudraVigilance and FAERS interfaces. It will also outline…

Managing Vendors and BPO Partners in Case Processing Chains Managing Vendors and BPO Partners in Case Processing Chains Context In an ever-evolving regulatory landscape, pharmacovigilance (PV) is a critical function that ensures ongoing drug safety and risk management throughout a product’s lifecycle. The integration of external vendors and business process outsourcing (BPO) partners into case processing chains introduces both opportunities and complexities for maintaining compliance with Good Vigilance Practices (GVP) and other regulatory requirements. Understanding the regulatory framework, documentation, and communication pathways with vendors is essential for achieving regulatory objectives. Legal/Regulatory Basis The primary regulatory guidelines that influence pharmacovigilance practices…

How to Configure Safety Systems for E2B(R3) and Regional Rules How to Configure Safety Systems for E2B(R3) and Regional Rules Context In the ever-evolving landscape of pharmacovigilance, ensuring compliance with regulatory affairs is paramount for pharmaceutical and biotechnology companies. Regulatory Affairs (RA) professionals must navigate complex guidelines and frameworks to ensure that systems for case processing and individual case safety report (ICSR) submissions are both effective and compliant. This document aims to provide a structured overview of the regulatory expectations surrounding the configuration of safety systems aligned with E2B(R3) standards and regional rules across the US, UK, and EU, while…

Reducing Duplicate Cases and Data Quality Issues Before Submission Reducing Duplicate Cases and Data Quality Issues Before Submission Context In the realm of pharmacovigilance, compliance with regulatory standards is paramount for ensuring drug safety and effective risk management. The submission and processing of Individual Case Safety Reports (ICSRs) are critical components of pharmacovigilance that significantly influence the assessment of drug safety profiles. The presence of duplicate cases and data quality issues not only hinders the efficacy of these processes but also poses substantial risks to public health and regulatory compliance. This article delineates the regulatory context, applicable guidelines, and best…

Training PV Staff on Clinical and Regulatory Context for Serious Cases Training PV Staff on Clinical and Regulatory Context for Serious Cases Context Pharmacovigilance (PV) is critical in ensuring drug safety and compliance with regulatory standards. Understanding the clinical and regulatory contexts is essential for PV staff, particularly when handling serious adverse events (SAEs). Regulatory affairs (RA) professionals play a significant role in ensuring that pharmacovigilance practices adhere to local and international guidelines, including the Good Pharmacovigilance Practices (GVP) and regulations set forth by agencies like the FDA, EMA, and MHRA. This article serves as a comprehensive manual for training…